Ignite Creation Date:
2025-12-25 @ 2:18 AM
Ignite Modification Date:
2026-01-23 @ 8:39 AM
Study NCT ID:
NCT01549834
Status:
COMPLETED
Last Update Posted:
2014-10-31
First Post:
2012-03-07
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D000544', 'term': 'Alzheimer Disease'}], 'ancestors': [{'id': 'D003704', 'term': 'Dementia'}, {'id': 'D001927', 'term': 'Brain Diseases'}, {'id': 'D002493', 'term': 'Central Nervous System Diseases'}, {'id': 'D009422', 'term': 'Nervous System Diseases'}, {'id': 'D024801', 'term': 'Tauopathies'}, {'id': 'D019636', 'term': 'Neurodegenerative Diseases'}, {'id': 'D019965', 'term': 'Neurocognitive Disorders'}, {'id': 'D001523', 'term': 'Mental Disorders'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C000618299', 'term': 'ABT-126'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'TRIPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 434}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2012-03'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2014-10', 'dispFirstSubmitDate': '2014-10-24', 'completionDateStruct': {'date': '2013-10', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2014-10-24', 'studyFirstSubmitDate': '2012-03-07', 'dispFirstSubmitQcDate': '2014-10-24', 'studyFirstSubmitQcDate': '2012-03-07', 'dispFirstPostDateStruct': {'date': '2014-10-31', 'type': 'ESTIMATED'}, 'lastUpdatePostDateStruct': {'date': '2014-10-31', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2012-03-09', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2013-10', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': "Alzheimer's Disease Assessment Scale - cognitive subscale", 'timeFrame': 'Measurements up through 24 weeks', 'description': 'An assessment tool which focuses on cognitive function and memory'}], 'secondaryOutcomes': [{'measure': 'Mini Mental Status Exam', 'timeFrame': 'Measurements up through 24 weeks', 'description': 'Questionnaire which provides a quantitative measure of cognition'}, {'measure': "Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL)", 'timeFrame': 'Measurements up through 24 weeks', 'description': 'Caregiver-based assessment of activities of daily living'}, {'measure': 'DEMentia Quality of Life (DEMQOL)', 'timeFrame': 'Measurements up through 24 weeks', 'description': 'Health-related quality of life measurement tool'}, {'measure': 'Clinician Interview-Based Impression of Change - plus (CIBIC-plus)', 'timeFrame': 'Measurements up through 24 weeks', 'description': 'Measures a global impression of change in severity of dementia'}, {'measure': 'Neuropsychiatry Inventory (NPI)', 'timeFrame': 'Measurements up through 24 weeks', 'description': "Assesses the presence of psychopathology in subjects with Alzheimer's disease and other dementias"}, {'measure': 'Partner-Patient Questionnaire for Shared Activities (PPQSA)', 'timeFrame': 'Measurements up through 24 weeks', 'description': 'Measures the extent to which mood and mental state interferes with the patient-partner relationship'}, {'measure': 'Resource Use in Dementia (RUD-Lite)', 'timeFrame': 'Measurements up through 24 weeks', 'description': 'Brief measurement tool for resource utilization'}, {'measure': 'EuroQol-5D Questionnaires', 'timeFrame': 'Measurements up through 24 weeks', 'description': "Assesses patient's mobility, self-care, usual activity, pain/discomfort and anxiety/depression"}, {'measure': 'Wechsler Memory Scale-III (WMS-III) Working Memory Index', 'timeFrame': 'Measurements up through 18 weeks', 'description': 'Assesses working memory'}]}, 'oversightModule': {'oversightHasDmc': True}, 'conditionsModule': {'conditions': ["Alzheimer's Disease"]}, 'referencesModule': {'references': [{'pmid': '26967214', 'type': 'DERIVED', 'citation': "Florian H, Meier A, Gauthier S, Lipschitz S, Lin Y, Tang Q, Othman AA, Robieson WZ, Gault LM. Efficacy and Safety of ABT-126 in Subjects with Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors: A Randomized, Double-Blind, Placebo-Controlled Study. J Alzheimers Dis. 2016;51(4):1237-47. doi: 10.3233/JAD-150978."}]}, 'descriptionModule': {'briefSummary': "This is an efficacy and safety study evaluating a new treatment for subjects with mild to moderate Alzheimer's disease.", 'detailedDescription': "This is a Phase 2 study designed to evaluate the efficacy and safety of ABT-126 in approximately 420 adults with mild to moderate Alzheimer's disease who are taking stable doses of acetylcholinesterase inhibitors. Subjects will be randomized to one of two ABT-126 dose arms or placebo for a 24-week treatment period."}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '90 Years', 'minimumAge': '55 Years', 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion Criteria:\n\n* The subject and caregiver must voluntarily sign and date an informed consent. If the subject does not have the capacity to provide informed consent, full informed consent must be obtained from the subject's representative and assent must be obtained from the subject.\n* The subject is a male or female between the ages of 55 and 90 years, inclusive, at Screening Visit 1. Main Inclusion (Continued):\n* The subject meets the Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS/ADRDA) criteria for probable AD.\n* The subject must be receiving a stable dose of an AChEI (donepezil or rivastigmine) for at least 90 days prior to Screening Visit 1.\n* The subject has a Mini-Mental Status Examination (MMSE) total score of 12 to 24, inclusive, at Screening Visit 1.\n* The subject has a Cornell Scale for Depression in Dementia (CSDD) score ≤ 10 at Screening Visit 1.\n* The subject has a Modified Hachinski Ischemic Scale (MHIS) score of ≤ 4 at Screening Visit 1.\n* With the exception of a diagnosis of mild-to-moderate Alzheimer's disease and the presence of stable medical conditions, the subject is in general good health, based upon the results of medical history, physical examination, vital signs, laboratory profile, and a 12-lead electrocardiogram (ECG).\n* The subject has an identified, reliable caregiver who will provide support and ensure compliance with the study medication and procedures, and provide accurate information about the subject's status during the study.\n\nExclusion Criteria:\n\n* The subject has taken galantamine or memantine within 60 days prior to Screening Visit 1.\n* The subject has received excluded concomitant medications.\n* The subject has clinically significant abnormal laboratory values at Screening Visit 1 as determined by the investigator.\n* The subject has a history of any significant neurologic disease other than Alzheimer's disease including Parkinson's disease, multi-infarct or vascular dementia, Huntington's disease, normal pressure hydrocephalus, progressive supranuclear palsy, multiple sclerosis, any seizures, mental retardation or a history of significant head trauma followed by persistent neurologic deficits or known structural brain abnormalities.\n* In the opinion of the investigator, the subject has any clinically significant uncontrolled medical or psychiatric illness."}, 'identificationModule': {'nctId': 'NCT01549834', 'briefTitle': "Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors", 'organization': {'class': 'INDUSTRY', 'fullName': 'AbbVie'}, 'officialTitle': "A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors", 'orgStudyIdInfo': {'id': 'M11-793'}, 'secondaryIdInfos': [{'id': '2011-004849-40', 'type': 'EUDRACT_NUMBER'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'ABT-126 Low Dose', 'description': 'low dose', 'interventionNames': ['Drug: ABT-126']}, {'type': 'EXPERIMENTAL', 'label': 'ABT-126 High Dose', 'description': 'high dose', 'interventionNames': ['Drug: ABT-126']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'sugar pill', 'description': 'Placebo', 'interventionNames': ['Drug: placebo']}], 'interventions': [{'name': 'ABT-126', 'type': 'DRUG', 'description': 'Low Dose', 'armGroupLabels': ['ABT-126 Low Dose']}, {'name': 'ABT-126', 'type': 'DRUG', 'description': 'High Dose', 'armGroupLabels': ['ABT-126 High Dose']}, {'name': 'placebo', 'type': 'DRUG', 'description': 'Placebo', 'armGroupLabels': ['sugar pill']}]}, 'contactsLocationsModule': {'locations': [{'zip': '93720', 'city': 'Fresno', 'state': 'California', 'country': 'United States', 'facility': 'Site Reference ID/Investigator# 66528', 'geoPoint': {'lat': 36.74773, 'lon': -119.77237}}, {'zip': '90806', 'city': 'Long Beach', 'state': 'California', 'country': 'United States', 'facility': 'Site Reference ID/Investigator# 69602', 'geoPoint': {'lat': 33.76696, 'lon': -118.18923}}, {'zip': '94109-4841', 'city': 'San Francisco', 'state': 'California', 'country': 'United States', 'facility': 'Site Reference ID/Investigator# 66527', 'geoPoint': {'lat': 37.77493, 'lon': -122.41942}}, {'zip': '06518', 'city': 'Hamden', 'state': 'Connecticut', 'country': 'United States', 'facility': 'Site Reference ID/Investigator# 66530', 'geoPoint': {'lat': 41.39593, 'lon': -72.89677}}, {'zip': '33445', 'city': 'Delray Beach', 'state': 'Florida', 'country': 'United States', 'facility': 'Site Reference ID/Investigator# 66522', 'geoPoint': {'lat': 26.46146, 'lon': -80.07282}}, {'zip': '32806', 'city': 'Orlando', 'state': 'Florida', 'country': 'United States', 'facility': 'Site Reference ID/Investigator# 66524', 'geoPoint': {'lat': 28.53834, 'lon': -81.37924}}, {'zip': '33613', 'city': 'Tampa', 'state': 'Florida', 'country': 'United States', 'facility': 'Site Reference ID/Investigator# 66531', 'geoPoint': {'lat': 27.94752, 'lon': -82.45843}}, {'zip': '33407', 'city': 'West Palm Beach', 'state': 'Florida', 'country': 'United States', 'facility': 'Site Reference ID/Investigator# 66529', 'geoPoint': {'lat': 26.71534, 'lon': -80.05337}}, {'zip': '60007', 'city': 'Elk Grove Village', 'state': 'Illinois', 'country': 'United States', 'facility': 'Site Reference ID/Investigator# 66526', 'geoPoint': {'lat': 42.00392, 'lon': -87.97035}}, {'zip': '10312', 'city': 'Staten Island', 'state': 'New York', 'country': 'United States', 'facility': 'Site Reference ID/Investigator# 66525', 'geoPoint': {'lat': 40.56233, 'lon': -74.13986}}, {'zip': '05201', 'city': 'Bennington', 'state': 'Vermont', 'country': 'United States', 'facility': 'Site Reference ID/Investigator# 66523', 'geoPoint': {'lat': 42.87813, 'lon': -73.19677}}, {'zip': 'J9A 1K7', 'city': 'Gatineau', 'country': 'Canada', 'facility': 'Site Reference ID/Investigator# 71793', 'geoPoint': {'lat': 45.47723, 'lon': -75.70164}}, {'zip': 'H3T 1E2', 'city': 'Montreal', 'country': 'Canada', 'facility': 'Site Reference ID/Investigator# 71794', 'geoPoint': {'lat': 45.50884, 'lon': -73.58781}}, {'zip': 'K9H 2P4', 'city': 'Peterborough', 'country': 'Canada', 'facility': 'Site Reference ID/Investigator# 71798', 'geoPoint': {'lat': 44.30012, 'lon': -78.31623}}, {'zip': 'M3B 2S7', 'city': 'Toronto', 'country': 'Canada', 'facility': 'Site Reference ID/Investigator# 71795', 'geoPoint': {'lat': 43.70643, 'lon': -79.39864}}, {'zip': 'H4H 1R3', 'city': 'Verdun', 'country': 'Canada', 'facility': 'Site Reference ID/Investigator# 71796', 'geoPoint': {'lat': 45.46005, 'lon': -73.57058}}, {'zip': '21033', 'city': 'Dijon', 'country': 'France', 'facility': 'Site Reference ID/Investigator# 71573', 'geoPoint': {'lat': 47.31344, 'lon': 5.01391}}, {'zip': '87042', 'city': 'Limoges', 'country': 'France', 'facility': 'Site Reference ID/Investigator# 77833', 'geoPoint': {'lat': 45.83362, 'lon': 1.24759}}, {'zip': '75013', 'city': 'Paris', 'country': 'France', 'facility': 'Site Reference ID/Investigator# 68706', 'geoPoint': {'lat': 48.85341, 'lon': 2.3488}}, {'zip': '75475', 'city': 'Paris', 'country': 'France', 'facility': 'Site Reference ID/Investigator# 68704', 'geoPoint': {'lat': 48.85341, 'lon': 2.3488}}, {'zip': '31059', 'city': 'Toulouse', 'country': 'France', 'facility': 'Site Reference ID/Investigator# 68705', 'geoPoint': {'lat': 43.60426, 'lon': 1.44367}}, {'zip': '14050', 'city': 'Berlin', 'country': 'Germany', 'facility': 'Site Reference ID/Investigator# 68768', 'geoPoint': {'lat': 52.52437, 'lon': 13.41053}}, {'zip': '79106', 'city': 'Freiburg im Breisgau', 'country': 'Germany', 'facility': 'Site Reference ID/Investigator# 68764', 'geoPoint': {'lat': 47.9959, 'lon': 7.85222}}, {'zip': '35625', 'city': 'Hüttenberg', 'country': 'Germany', 'facility': 'Site Reference ID/Investigator# 68767', 'geoPoint': {'lat': 50.51453, 'lon': 8.62189}}, {'zip': '09648', 'city': 'Mittweida', 'country': 'Germany', 'facility': 'Site Reference ID/Investigator# 69960', 'geoPoint': {'lat': 50.98622, 'lon': 12.97537}}, {'zip': '81675', 'city': 'Munich', 'country': 'Germany', 'facility': 'Site Reference ID/Investigator# 68765', 'geoPoint': {'lat': 48.13743, 'lon': 11.57549}}, {'zip': '19053', 'city': 'Schwerin', 'country': 'Germany', 'facility': 'Site Reference ID/Investigator# 69959', 'geoPoint': {'lat': 53.62937, 'lon': 11.41316}}, {'zip': '115 21', 'city': 'Athens', 'country': 'Greece', 'facility': 'Site Reference ID/Investigator# 68730', 'geoPoint': {'lat': 37.98376, 'lon': 23.72784}}, {'zip': '151 25', 'city': 'Athens', 'country': 'Greece', 'facility': 'Site Reference ID/Investigator# 68732', 'geoPoint': {'lat': 37.98376, 'lon': 23.72784}}, {'zip': '15123', 'city': 'Athens', 'country': 'Greece', 'facility': 'Site Reference ID/Investigator# 68733', 'geoPoint': {'lat': 37.98376, 'lon': 23.72784}}, {'zip': '12462', 'city': 'Haidari, Athens', 'country': 'Greece', 'facility': 'Site Reference ID/Investigator# 68731', 'geoPoint': {'lat': 37.98376, 'lon': 23.72784}}, {'zip': '56403', 'city': 'Thessaloniki', 'country': 'Greece', 'facility': 'Site Reference ID/Investigator# 68729', 'geoPoint': {'lat': 40.64072, 'lon': 22.93493}}, {'zip': '570 10', 'city': 'Thessaloniki', 'country': 'Greece', 'facility': 'Site Reference ID/Investigator# 68735', 'geoPoint': {'lat': 40.64072, 'lon': 22.93493}}, {'zip': '7530', 'city': 'Belville', 'country': 'South Africa', 'facility': 'Site Reference ID/Investigator# 67586', 'geoPoint': {'lat': -33.89404, 'lon': 18.63486}}, {'zip': '7405', 'city': 'Cape Town', 'country': 'South Africa', 'facility': 'Site Reference ID/Investigator# 67582', 'geoPoint': {'lat': -33.92584, 'lon': 18.42322}}, {'zip': '6529', 'city': 'George', 'country': 'South Africa', 'facility': 'Site Reference ID/Investigator# 67584', 'geoPoint': {'lat': -33.963, 'lon': 22.46173}}, {'zip': '2196', 'city': 'Johannesburg', 'country': 'South Africa', 'facility': 'Site Reference ID/Investigator# 67585', 'geoPoint': {'lat': -26.20227, 'lon': 28.04363}}, {'zip': '2196', 'city': 'Rosebank', 'country': 'South Africa', 'facility': 'Site Reference ID/Investigator# 67583', 'geoPoint': {'lat': -33.95556, 'lon': 18.47417}}, {'zip': 'BA1 3NG', 'city': 'Bath', 'country': 'United Kingdom', 'facility': 'Site Reference ID/Investigator# 67787', 'geoPoint': {'lat': 51.3751, 'lon': -2.36172}}, {'zip': 'G20 0XA', 'city': 'Glasgow', 'country': 'United Kingdom', 'facility': 'Site Reference ID/Investigator# 67784', 'geoPoint': {'lat': 55.86515, 'lon': -4.25763}}, {'zip': 'TW8 8DS', 'city': 'London', 'country': 'United Kingdom', 'facility': 'Site Reference ID/Investigator# 67786', 'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}, {'zip': 'M8 5RB', 'city': 'Manchester', 'country': 'United Kingdom', 'facility': 'Site Reference ID/Investigator# 67785', 'geoPoint': {'lat': 53.48095, 'lon': -2.23743}}, {'zip': 'WA2 8WA', 'city': 'Warrington', 'country': 'United Kingdom', 'facility': 'Site Reference ID/Investigator# 67783', 'geoPoint': {'lat': 53.39254, 'lon': -2.58024}}], 'overallOfficials': [{'name': 'Laura Gault, MD', 'role': 'STUDY_DIRECTOR', 'affiliation': 'AbbVie'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'AbbVie (prior sponsor, Abbott)', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}